Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 10/20 | 0.55 |
| ▸ | CACNA1H | O95180 | 8/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21512853 | 1.00 | CACNA1B (0.55) | CACNA1BCACNA1HPIK3CAMEN1KMT2A | |
| SCHEMBL21513762 | 0.90 | ALDH1A1 (0.48) | CACNA1BCACNA1HMEN1KMT2AALDH1A1 | |
| SCHEMBL29968192 | 0.90 | ALDH1A1 (0.48) | CACNA1BCACNA1HMEN1KMT2AALDH1A1 | |
| SCHEMBL29970032 | 0.89 | CACNA1B (0.51) | CACNA1BCACNA1HPIK3CAMEN1KMT2A | |
| SCHEMBL21512864 | 0.89 | CACNA1B (0.43) | CACNA1BCACNA1HPIK3CAMEN1KMT2A | |
| SCHEMBL21513750 | 0.89 | CACNA1B (0.56) | CACNA1BCACNA1HPIK3CAALDH1A1MTOR | |
| SCHEMBL29969883 | 0.89 | CACNA1B (0.56) | CACNA1BCACNA1HPIK3CAALDH1A1MTOR | |
| SCHEMBL21513746 | 0.88 | CACNA1B (0.48) | CACNA1BCACNA1HPIK3CAALDH1A1MTOR | |
| SCHEMBL29969263 | 0.88 | CACNA1B (0.48) | CACNA1BCACNA1HPIK3CAALDH1A1MTOR | |
| SCHEMBL21512821 | 0.88 | EDNRB (0.46) | CACNA1BCACNA1HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | CACNA1B 4878/4885CACNA1H 4862/4885PIK3CA 480/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | CACNA1B 4878/4885CACNA1H 4862/4885PIK3CA 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.